UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008338

2024

Volltextzugriff (PDF)

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

The Lancet. Haematology, 2022-05, Vol.9 (5), p.e327-e339

2022

Volltextzugriff (PDF)

Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans

Blood, 2011-06, Vol.117 (22), p.5881-5891

2011

Volltextzugriff (PDF)

Correction regarding data on blinatumomab-associated seizures

Nature reviews. Clinical oncology, 2016-10, Vol.13 (10), p.650-650

2016

Volltextzugriff (PDF)

Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus

Blood, 2006-03, Vol.107 (6), p.2562-2569

2006

Volltextzugriff (PDF)

Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus

The Journal of clinical investigation, 2002-08, Vol.110 (4), p.537-548

2002

Volltextzugriff (PDF)

Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells

Blood, 2002-12, Vol.100 (12), p.3960-3967

2002

Volltextzugriff (PDF)

Coronary B-cell lymphoma infiltration causing myocardial infarction

European heart journal, 2020-03, Vol.41 (9), p.1059-1059

2020

Volltextzugriff (PDF)

Outcome of BCMA Bite (AMG420) Therapy in Relapse and Refractory Multiple Myeloma (RRMM) Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.25-26

2020

Volltextzugriff (PDF)

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.3372-3372

2023

Volltextzugriff (PDF)

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Blood, 2023-11, Vol.142 (Supplement 1), p.95-95

2023

Volltextzugriff (PDF)

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.964-964

2023

Volltextzugriff (PDF)

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7549-7549

2023

Volltextzugriff (PDF)

CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement

Blood, 2018-11, Vol.132 (Supplement 1), p.2881-2881

2018

Volltextzugriff (PDF)

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Blood, 2022-11, Vol.140 (Supplement 1), p.1775-1777

2022

Volltextzugriff (PDF)

Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.6531-6531

2024

Volltextzugriff (PDF)

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood, 2023-11, Vol.142 (Supplement 1), p.828-828

2023

Volltextzugriff (PDF)

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3085-3085

2023

Volltextzugriff (PDF)

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Blood, 2023-11, Vol.142 (Supplement 1), p.2120-2120

2023

Volltextzugriff (PDF)

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.4461-4461

2023

Volltextzugriff (PDF)

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.4437-4437

2023

Volltextzugriff (PDF)

O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3

Annals of oncology, 2023-11, Vol.34, p.S1389-S1389

2023

Volltextzugriff (PDF)

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7023-7023

2023

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(165)
Berichte
(3)

Sprache

Englisch
(167)
Deutsch
(1)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Virus variant–specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022

Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans

Correction regarding data on blinatumomab-associated seizures

Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus

P367: LONG‐TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA‐3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT

Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus

Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells

Coronary B-cell lymphoma infiltration causing myocardial infarction

Outcome of BCMA Bite (AMG420) Therapy in Relapse and Refractory Multiple Myeloma (RRMM) Patients

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study

CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Aktive Filter

Suchergebnisse filtern